Thymalfasin

Generic Name
Thymalfasin
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
62304-98-7
Unique Ingredient Identifier
W0B22ISQ1C
Background

Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases.

Indication

⑴慢性乙型肝炎(简称乙肝)。本品是用来治疗那些18岁或以上的慢性乙型肝炎患者,患者的肝病有代偿性,和有乙型肝炎病毒复制(血清HBV-DNA阳性),在那些血清乙肝表面抗原(HBsAg)阳性最少6个月,且有ALT升高的患者所做的研究显示,本品治疗可以产生病毒性缓解(血清HBV-DNA失去)和ALT水平复常,在一些做出应答的患者,本品治疗可除去血清表面抗原。本品与α-干扰素联用时可能比单用本品或单用干扰素增加应答率。

⑵作为免疫损害患者的疫苗增强剂。免疫系统功能受到抑制者,包括接受慢性血液透析和老年病患者,本品增强患者对病毒性疫苗,例如流感疫苗或乙肝疫苗的免疫应答。血液透析患者在接种流感疫苗后,应用本品作为佐剂者有65%患者产生抗流感病毒抗体,滴度水平增加4倍以上,安慰剂组只有24%患者做出此反应。

Associated Conditions
Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection
Associated Therapies
Adjuvant Therapy

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

First Posted Date
2023-09-28
Last Posted Date
2023-11-18
Lead Sponsor
Beijing Friendship Hospital
Target Recruit Count
20
Registration Number
NCT06056804
Locations
🇨🇳

Beijing Friendship Hospital,Capital Medical University, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, China

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Not yet recruiting
Conditions
Interventions
First Posted Date
2023-09-06
Last Posted Date
2023-09-06
Lead Sponsor
Beijing Friendship Hospital
Target Recruit Count
26
Registration Number
NCT06024356
Locations
🇨🇳

Beijing Friendship Hospital, Capital medical University, Beijing, Xicheng Dis, China

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

First Posted Date
2023-03-30
Last Posted Date
2023-03-30
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
60
Registration Number
NCT05790447
Locations
🇨🇳

The Second Affiliated Hospital of SchoowUniversity, Suzhou, China

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2020-07-27
Last Posted Date
2023-02-14
Lead Sponsor
Rhode Island Hospital
Target Recruit Count
56
Registration Number
NCT04487444
Locations
🇺🇸

The Miriam Hospital, Providence, Rhode Island, United States

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-06-11
Last Posted Date
2022-09-27
Lead Sponsor
William B. Ershler, MD
Target Recruit Count
262
Registration Number
NCT04428008
Locations
🇺🇸

Clinical Research Consultants, Kansas City, Kansas, United States

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

First Posted Date
2015-09-10
Last Posted Date
2017-11-28
Lead Sponsor
Hangzhou Cancer Hospital
Target Recruit Count
29
Registration Number
NCT02545751
Locations
🇨🇳

Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China

Abscopal Effect for Metastatic Small Cell Lung Cancer

First Posted Date
2015-09-04
Last Posted Date
2019-03-21
Lead Sponsor
Zhejiang Provincial People's Hospital
Registration Number
NCT02542137

Abscopal Effect for Metastatic Colorectal Cancer

First Posted Date
2015-08-31
Last Posted Date
2023-09-21
Lead Sponsor
Zhejiang Provincial People's Hospital
Registration Number
NCT02535988

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

First Posted Date
2014-11-02
Last Posted Date
2014-11-21
Lead Sponsor
Jia Fan
Target Recruit Count
360
Registration Number
NCT02281266
Locations
🇨🇳

Zhongshan Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath